Risk-Benefit of Asthma Therapy in Children: Nonsteroidal Anti-Inflammatory Drugs

  • James P. Kemp
Part of the Allergy Frontiers book series (ALLERGY, volume 5)

Asthma is a chronic inflammatory disease of the airways, and anti-inflammatory treatment is an integral part of asthma treatment for both adults and children. Current international asthma management guidelines recommend low-dose inhaled corticosteroids (ICS) or a leukotriene modifier for children over age 5 and low-dose ICS for children age 5 and younger, who require a controller medication [1, 2]. While the guidelines list ICS as being the most effective controller medications [1, 2], for many children, nonsteroidal anti-inflammatory treatments are an effective alternative to or adjunctive therapy with ICS to achieve asthma control.

Nonsteroidal anti-inflammatory treatments used in childhood asthma include the leukotriene modifiers, cromolyn, nedocromil, ketotifen, theophylline, and, for children age 12 and older, omalizumab. This chapter will cover the benefits and risks of these nonsteroidal anti-inflammatory drugs for treatment of asthma in children. Other than the leukotriene modifiers and omalizumab, most of these agents have been in use for longer than ICS. Nonetheless, their mechanisms of action are not fully understood, and their efficacy is not always well-defined, particularly for children.


Allergic Rhinitis Fluticasone Propionate Allergy Clin Immunol Childhood Asthma Sodium Cromoglycate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Global Initiative for Asthma. GINA report, Global Strategy for Asthma Management and Prevention 2006; Available at
  2. 2.
    Global Initiative for Asthma. Pocket Guide for Asthma Management and Prevention in Children 2006; Available at
  3. 3.
    Fuhlbrigge AL, Guilbert T, Spahn J, Peden D, Davis K (2006) The influence of variation in type and pattern of symptoms on assessment in pediatric asthma. Pediatrics 118:619–625CrossRefPubMedGoogle Scholar
  4. 4.
    Rabe KF, Adachi M, Lai CK, Soriano JB, Vermeire PA, Weiss KB, Weiss ST (2004) Worldwide severity and control of asthma in children and adults: the global asthma insights and reality surveys. J Allergy Clin Immunol 114:40–47CrossRefPubMedGoogle Scholar
  5. 5.
    Global Initiative for Asthma. 2005 Update: Workshop Report, Global Strategy for Asthma Management and Prevention; Available at
  6. 6.
    British Thoracic Society, Scottish Intercollegiate Guidelines Network. 2005 update to the British Guideline on the Management of Asthma. Available at fulltext/63/index.html
  7. 7.
    Canadian Consensus Asthma Guidelines Dissemination and Implementation Committee. Canadian Asthma Consensus Report, 1999; Available at
  8. 8.
    Becker A, Berube D, Chad Z, Dolovich M, Ducharme F, D'Urzo T, Ernst P, Ferguson A, Gillespie C, Kapur S, Kovesi T, Lyttle B, Mazer B, Montgomery M, Pedersen S, Pianosi P, Reisman JJ, Sears M, Simons E, Spier S, Thivierge R, Watson W, Zimmerman B (2005) Canadian Pediatric Asthma Consensus guidelines, 2003 (updated to December 2004): introduction. CMAJ 173:S12–S14PubMedGoogle Scholar
  9. 9.
    Humbert M, Holgate S, Boulet LP, Bousquet J (2007) Asthma control or severity: that is the question. Allergy 62:95–101PubMedGoogle Scholar
  10. 10.
    Martinez FD (2002) Development of wheezing disorders and asthma in preschool children. Pediatrics 109:362–367PubMedGoogle Scholar
  11. 11.
    Kaditis AG, Gourgoulianis K, Winnie G (2003) Anti-inflammatory treatment for recurrent wheezing in the first five years of life. Pediatr Pulmonol 35:241–252CrossRefPubMedGoogle Scholar
  12. 12.
    de Longueville M (2000) What are the candidate groups for pharmacotherapeutic intervention to prevent asthma? Pediatr Allergy Immunol 11 Suppl 13:41–44CrossRefPubMedGoogle Scholar
  13. 13.
    Busse W, Banks-Schlegel S, Noel P, Ortega H, Taggart V, Elias J (2004) Future research directions in asthma: an NHLBI Working Group report. Am J Respir Crit Care Med 170:683–690CrossRefPubMedGoogle Scholar
  14. 14.
    Zeiger RS, Dawson C, Weiss S (1999) Relationships between duration of asthma and asthma severity among children in the Childhood Asthma Management Program (CAMP). J Allergy Clin Immunol 103:376–387CrossRefPubMedGoogle Scholar
  15. 15.
    Bisgaard H, Hermansen MN, Loland L, Halkjaer LB, Buchvald F (2006) Intermittent inhaled corticosteroids in infants with episodic wheezing. N Engl J Med 354:1998–2005CrossRefPubMedGoogle Scholar
  16. 16.
    Guilbert TW, Morgan WJ, Zeiger RS, Mauger DT, Boehmer SJ, Szefler SJ, Bacharier LB, Lemanske RF, Jr., Strunk RC, Allen DB, Bloomberg GR, Heldt G, Krawiec M, Larsen G, Liu AH, Chinchilli VM, Sorkness CA, Taussig LM, Martinez FD (2006) Long-term inhaled cor-ticosteroids in preschool children at high risk for asthma. N Engl J Med 354:1985–1997CrossRefPubMedGoogle Scholar
  17. 17.
    Henderson WR, Jr., Tang LO, Chu SJ, Tsao SM, Chiang GK, Jones F, Jonas M, Pae C, Wang H, Chi EY (2002) A role for cysteinyl leukotrienes in airway remodeling in a mouse asthma model. Am J Respir Crit Care Med 165:108–116PubMedGoogle Scholar
  18. 18.
    Henderson WR, Jr., Chiang GK, Tien YT, Chi EY (2006) Reversal of allergen-induced airway remodeling by CysLT1 receptor blockade. Am J Respir Crit Care Med 173:718–728CrossRefPubMedGoogle Scholar
  19. 19.
    Alton EW, Norris AA (1996) Chloride transport and the actions of nedocromil sodium and cromolyn sodium in asthma. J Allergy Clin Immunol 98:S102–S105PubMedCrossRefGoogle Scholar
  20. 20.
    Norris AA (1996) Pharmacology of sodium cromoglycate. Clin Exp Allergy 26 Suppl 4:5–7CrossRefPubMedGoogle Scholar
  21. 21.
    National Asthma Education and Prevention Program (2002) Expert Panel Report: Guidelines for the Diagnosis and Management of Asthma Update on Selected Topics--2002. J Allergy Clin Immunol 110:S141–S219CrossRefGoogle Scholar
  22. 22.
    Tasche MJ, Uijen JH, Bernsen RM, de Jongste JC, van der Wouden JC (2000) Inhaled disodium cromoglycate (DSCG) as maintenance therapy in children with asthma: a systematic review. Thorax 55:913–920CrossRefPubMedGoogle Scholar
  23. 23.
    Sridhar AV, McKean M (2006) Nedocromil sodium for chronic asthma in children. Cochrane Database of Systematic Reviews, Issue 3. Art. No.: CD004108. DOI: 10.1002/14651858. CD004108.pub2Google Scholar
  24. 24.
    Spooner C, Rowe BH, Saunders LD (2000) Nedocromil sodium in the treatment of exercise-induced asthma: a meta-analysis. Eur Respir J 16:30–37CrossRefPubMedGoogle Scholar
  25. 25.
    Kelly KD, Spooner CH, Rowe BH (2001) Nedocromil sodium versus sodium cromoglycate in treatment of exercise-induced bronchoconstriction: a systematic review. Eur Respir J 17:39–45CrossRefPubMedGoogle Scholar
  26. 26.
    Spooner CH, Spooner GR, Rowe BH (2003) Mast-cell stabilising agents to prevent exercise-induced bronchoconstriction. Cochrane Database of Systematic Reviews, Issue 4. Art. No.: CD002307. DOI: 10.1002/14651858.CD002307Google Scholar
  27. 27.
    Bukstein DA, Bratton DL, Firriolo KM, Estojak J, Bird SR, Hustad CM, Edelman JM (2003) Evaluation of parental preference for the treatment of asthmatic children aged 6 to 11 years with oral montelukast or inhaled cromolyn: a randomized, open-label, crossover study. J Asthma 40:475–485CrossRefPubMedGoogle Scholar
  28. 28.
    Kelloway JS, Wyatt RA, Adlis SA (1994) Comparison of patients' compliance with prescribed oral and inhaled asthma medications. Arch Intern Med 154:1349–1352CrossRefPubMedGoogle Scholar
  29. 29.
    Heyman SN, Karmeli F, Brezis M, Rachmilewitz D (1997) The effect of ketotifen on nitric oxide synthase activity. Br J Pharmacol 120:1545–1551CrossRefPubMedGoogle Scholar
  30. 30.
    Bassler D, Mitra A, Ducharme FM, Forster J, Schwarzer G (2004) Ketotifen alone or as additional medication for long-term control of asthma and wheeze in children. Cochrane Database of Systematic Reviews, Issue 1. Art. No.: CD001384. DOI: 10.1002/14651858.CD001384.pub2Google Scholar
  31. 31.
    Bustos GJ, Bustos D, Bustos GJ, Romero O (1995) Prevention of asthma with ketotifen in preasthmatic children: a three-year follow-up study. Clin Exp Allergy 25:568–573CrossRefPubMedGoogle Scholar
  32. 32.
    Ito K, Lim S, Caramori G, Cosio B, Chung KF, Adcock IM, Barnes PJ (2002) A molecular mechanism of action of theophylline: Induction of histone deacetylase activity to decrease inflammatory gene expression. Proc Natl Acad Sci U S A 99:8921–8926CrossRefPubMedGoogle Scholar
  33. 33.
    Barnes PJ (2003) Theophylline: new perspectives for an old drug. Am J Respir Crit Care Med 167:813–818CrossRefPubMedGoogle Scholar
  34. 34.
    Barnes PJ, Adcock IM, Ito K (2005) Histone acetylation and deacetylation: importance in inflammatory lung diseases. Eur Respir J 25:552–563CrossRefPubMedGoogle Scholar
  35. 35.
    Seddon P, Bara A, Ducharme FM, Lasserson TJ (2006) Oral xanthines as maintenance treatment for asthma in children. Cochrane Database of Systematic Reviews, Issue 1. Art. No.: CD002885. DOI: 10.1002/14651858.CD002885.pub2Google Scholar
  36. 36.
    Kemp JP, Kemp JA (2001) Management of asthma in children. Am Fam Physician 63:1341–1348, 1353–1344PubMedGoogle Scholar
  37. 37.
    Ellis EF (1985) Theophylline toxicity. J Allergy Clin Immunol 76:297–301CrossRefPubMedGoogle Scholar
  38. 38.
    Zhang Z Y, Kaminsky LS (1995) Characterization of human cytochromes P450 involved in theophylline 8-hydroxylation. Biochem Pharmacol 50:205–211CrossRefPubMedGoogle Scholar
  39. 39.
    Ogawa Y, Calhoun WJ (2006) The role of leukotrienes in airway inflammation. J Allergy Clin Immunol 118:789–798CrossRefPubMedGoogle Scholar
  40. 40.
    Busse W, Kraft M (2005) Cysteinyl leukotrienes in allergic inflammation: strategic target for therapy. Chest 127:1312–1326CrossRefPubMedGoogle Scholar
  41. 41.
    Kemp JP (2000) Leukotriene receptor antagonists for the treatment of asthma. IDrugs 3:430–441PubMedGoogle Scholar
  42. 42.
    Kemp JP (2003) Recent advances in the management of asthma using leukotriene modifiers. Am J Respir Med 2:139–156PubMedGoogle Scholar
  43. 43.
    Knorr B, Matz J, Bernstein JA, Nguyen H, Seidenberg BC, Reiss TF, Becker A (1998) Montelukast for chronic asthma in 6- to 14-year-old children: a randomized, double-blind trial. Pediatric Montelukast Study Group. JAMA 279:1181–1186CrossRefPubMedGoogle Scholar
  44. 44.
    Knorr B, Franchi LM, Bisgaard H, Vermeulen JH, LeSouef P, Santanello N, Michele TM, Reiss TF, Nguyen HH, Bratton DL (2001) Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years. Pediatrics 108:E48CrossRefPubMedGoogle Scholar
  45. 45.
    Meyer KA, Arduino JM, Santanello NC, Knorr BA, Bisgaard H (2003) Response to montelu-kast among subgroups of children aged 2 to 14 years with asthma. J Allergy Clin Immunol 111:757–762CrossRefPubMedGoogle Scholar
  46. 46.
    Becker A, Swern A, Tozzi CA, Yu Q, Reiss T, Knorr B (2004) Montelukast in asthmatic patients 6 years-14 years old with an FEV1 > 75%. Curr Med Res Opin 20:1651–1659CrossRefPubMedGoogle Scholar
  47. 47.
    Pearlman DS, Lampl KL, Dowling PJ, Jr., Miller CJ, Bonuccelli CM (2000) Effectiveness and tolerability of zafirlukast for the treatment of asthma in children. Clin Ther 22:732–747CrossRefPubMedGoogle Scholar
  48. 48.
    Simons FE, Villa JR, Lee BW, Teper AM, Lyttle B, Aristizabal G, Laessig W, Schuster A, Perez-Frias J, Sekerel BE, Menten J, Leff JA (2001) Montelukast added to budesonide in children with persistent asthma: a randomized, double-blind, crossover study. J Pediatr 138:694–698CrossRefPubMedGoogle Scholar
  49. 49.
    Strauch E, Moske O, Thoma S, Storm Van's Gravesande K, Ihorst G, Brandis M, Kuehr J (2003) A randomized controlled trial on the effect of montelukast on sputum eosinophil cat-ionic protein in children with corticosteroid-dependent asthma. Pediatr Res 54:198–203CrossRefPubMedGoogle Scholar
  50. 50.
    Ghiro L, Zanconato S, Rampon O, Piovan V, Pasquale MF, Baraldi E (2002) Effect of mon-telukast added to inhaled corticosteroids on fractional exhaled nitric oxide in asthmatic children. Eur Respir J 20:630–634CrossRefPubMedGoogle Scholar
  51. 51.
    Kemp JP, Dockhorn RJ, Shapiro GG, Nguyen HH, Reiss TF, Seidenberg BC, Knorr B (1998) Montelukast once daily inhibits exercise-induced bronchoconstriction in 6- to 14-year-old children with asthma. J Pediatr 133:424–428CrossRefPubMedGoogle Scholar
  52. 52.
    Pearlman DS, Ostrom NK, Bronsky EA, Bonuccelli CM, Hanby LA (1999) The leukotriene D4-receptor antagonist zafirlukast attenuates exercise-induced bronchoconstriction in children. J Pediatr 134:273–279CrossRefPubMedGoogle Scholar
  53. 53.
    de Benedictis FM, del Giudice MM, Forenza N, Decimo F, de Benedictis D, Capristo A (2006) Lack of tolerance to the protective effect of montelukast in exercise-induced broncho-constriction in children. Eur Respir J 28:291–295CrossRefPubMedGoogle Scholar
  54. 54.
    Luskin A, Bukstein D, Kocevar VS, Yin DD (2005) Asthma rescue and allergy medication use among asthmatic children with prior allergy prescriptions who initiated asthma controller therapy. Ann Allergy Asthma Immunol 95:129–136PubMedCrossRefGoogle Scholar
  55. 55.
    Nayak A (2004) A review of montelukast in the treatment of asthma and allergic rhinitis. Expert Opin Pharmacother 5:679–686CrossRefPubMedGoogle Scholar
  56. 56.
    Ciprandi G, Frati F, Marcucci F, Sensi L, Tosca MA, Milanese M, Ricca V (2003) Nasal cytokine modulation by montelukast in allergic children: a pilot study. Allerg Immunol (Paris) 35:295–299Google Scholar
  57. 57.
    Sazonov-Kocevar V, Laforest L, Travier N, Yin DD, Ganse EV (2006) Asthma and allergy medication use and costs among pediatric primary care patients on asthma controller therapy. Pediatr Allergy Immunol 17:620–628CrossRefPubMedGoogle Scholar
  58. 58.
    Straub DA, Moeller A, Minocchieri S, Hamacher J, Sennhauser FH, Hall GL, Wildhaber JH (2005) The effect of montelukast on lung function and exhaled nitric oxide in infants with early childhood asthma. Eur Respir J 25:289–294CrossRefPubMedGoogle Scholar
  59. 59.
    Bisgaard H, Zielen S, Garcia-Garcia ML, Johnston SL, Gilles L, Menten J, Tozzi CA, Polos P (2005) Montelukast reduces asthma exacerbations in 2- to 5-year-old children with intermittent asthma. Am J Respir Crit Care Med 171:315–322CrossRefPubMedGoogle Scholar
  60. 60.
    Zeiger RS, Szefler SJ, Phillips BR, Schatz M, Martinez FD, Chinchilli VM, Lemanske RF, Jr., Strunk RC, Larsen G, Spahn JD, Bacharier LB, Bloomberg GR, Guilbert TW, Heldt G, Morgan WJ, Moss MH, Sorkness CA, Taussig LM (2006) Response profiles to fluticasone and montelukast in mild-to-moderate persistent childhood asthma. J Allergy Clin Immunol 117:45–52CrossRefPubMedGoogle Scholar
  61. 61.
    Szefler SJ, Phillips BR, Martinez FD, Chinchilli VM, Lemanske RF, Strunk RC, Zeiger RS, Larsen G, Spahn JD, Bacharier LB, Bloomberg GR, Guilbert TW, Heldt G, Morgan WJ, Moss MH, Sorkness CA, Taussig LM (2005) Characterization of within-subject responses to fluti-casone and montelukast in childhood asthma. J Allergy Clin Immunol 115:233–242CrossRefPubMedGoogle Scholar
  62. 62.
    Ostrom NK, Decotiis BA, Lincourt WR, Edwards LD, Hanson KM, Carranza Rosenzweig JR, Crim C (2005) Comparative efficacy and safety of low-dose fluticasone propionate and mon-telukast in children with persistent asthma. J Pediatr 147:213–220CrossRefPubMedGoogle Scholar
  63. 63.
    Garcia Garcia ML, Wahn U, Gilles L, Swern A, Tozzi CA, Polos P (2005) Montelukast, compared with fluticasone, for control of asthma among 6- to 14-year-old patients with mild asthma: the MOSAIC study. Pediatrics 116:360–369CrossRefPubMedGoogle Scholar
  64. 64.
    Sorkness CA, Lemanske RF, Jr., Mauger DT, Boehmer SJ, Chinchilli VM, Martinez FD, Strunk RC, Szefler SJ, Zeiger RS, Bacharier LB, Bloomberg GR, Covar RA, Guilbert TW, Heldt G, Larsen G, Mellon MH, Morgan WJ, Moss MH, Spahn JD, Taussig LM (2007) Longterm comparison of 3 controller regimens for mild-moderate persistent childhood asthma: The Pediatric Asthma Controller Trial. J Allergy Clin Immunol 119:64–72CrossRefPubMedGoogle Scholar
  65. 65.
    Becker AB, Kuznetsova O, Vermeulen J, Soto-Quiros ME, Young B, Reiss TF, Dass SB, Knorr BA (2006) Linear growth in prepubertal asthmatic children treated with montelukast, beclomethasone, or placebo: a 56-week randomized double-blind study. Ann Allergy Asthma Immunol 96:800–807PubMedGoogle Scholar
  66. 66.
    Bukstein DA, Luskin AT, Bernstein A (2003) “Real-world” effectiveness of daily controller medicine in children with mild persistent asthma. Ann Allergy Asthma Immunol 90:543–549PubMedGoogle Scholar
  67. 67.
    Weinberg EG, Naya I (2000) Treatment preferences of adolescent patients with asthma. Pediatr Allergy Immunol 11:49–55CrossRefPubMedGoogle Scholar
  68. 68.
    Whelan GJ, Blake K, Kissoon N, Duckworth LJ, Wang J, Sylvester JE, Lima JJ (2003) Effect of montelukast on time-course of exhaled nitric oxide in asthma: influence of LTC4 synthase A(-444)C polymorphism. Pediatr Pulmonol 36:413–420CrossRefPubMedGoogle Scholar
  69. 69.
    Lima JJ, Zhang S, Grant A, Shao L, Tantisira KG, Allayee H, Wang J, Sylvester J, Holbrook J, Wise R, Weiss ST, Barnes K (2006) Influence of leukotriene pathway polymorphisms on response to montelukast in asthma. Am J Respir Crit Care Med 173:379–385CrossRefPubMedGoogle Scholar
  70. 70.
    Bisgaard H (2001) Leukotriene modifiers in pediatric asthma management. Pediatrics 107:381–390CrossRefPubMedGoogle Scholar
  71. 71.
    Boyer D, Vargas SO, Slattery D, Rivera-Sanchez YM, Colin AA (2006) Churg-Strauss syndrome in children: a clinical and pathologic review. Pediatrics 118:e914–e920CrossRefPubMedGoogle Scholar
  72. 72.
    Critical Therapeutics Inc (2005) Zyflo (zileuton tablets) Prescribing Information; Available at
  73. 73.
    Sherrill DL, Stein R, Halonen M, Holberg CJ, Wright A, Martinez FD (1999) Total serum IgE and its association with asthma symptoms and allergic sensitization among children. J Allergy Clin Immunol 104:28–36CrossRefPubMedGoogle Scholar
  74. 74.
    Holgate S, Casale T, Wenzel S, Bousquet J, Deniz Y, Reisner C (2005) The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. J Allergy Clin Immunol 115:459–465CrossRefPubMedGoogle Scholar
  75. 75.
    Holgate ST, Djukanovic R, Casale T, Bousquet J (2005) Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy. Clin Exp Allergy 35:408–416CrossRefPubMedGoogle Scholar
  76. 76.
    Milgrom H, Berger W, Nayak A, Gupta N, Pollard S, McAlary M, Taylor AF, Rohane P (2001) Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics 108:E36CrossRefPubMedGoogle Scholar
  77. 77.
    Silkoff PE, Romero FA, Gupta N, Townley RG, Milgrom H (2004) Exhaled nitric oxide in children with asthma receiving Xolair (omalizumab), a monoclonal anti-immunoglobulin E antibody. Pediatrics 113:e308–e312CrossRefPubMedGoogle Scholar
  78. 78.
    Berger W, Gupta N, McAlary M, Fowler-Taylor A (2003) Evaluation of long-term safety of the anti-IgE antibody, omalizumab, in children with allergic asthma. Ann Allergy Asthma Immunol 91:182–188PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2009

Authors and Affiliations

  • James P. Kemp
    • 1
    • 2
  1. 1.Department of PediatricsUniversity of California School of MedicineSan DiegoUSA
  2. 2.Allergy and Asthma Medical Group and Research CenterSan DiegoUSA

Personalised recommendations